 Drug Resistance, Neoplasm
"Drug Resistance, Neoplasm" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
| Descriptor ID |
D019008
|
| MeSH Number(s) |
G07.690.773.984.395
|
| Concept/Terms |
Drug Resistance, Neoplasm- Drug Resistance, Neoplasm
- Resistance, Antineoplastic Agent
- Resistance, Antineoplastic Drug
- Drug Resistance, Antineoplastic
- Neoplasm Drug Resistance
- Antineoplastic Agent Resistance
- Antineoplastic Drug Resistance
|
Below are MeSH descriptors whose meaning is more general than "Drug Resistance, Neoplasm".
Below are MeSH descriptors whose meaning is more specific than "Drug Resistance, Neoplasm".
This graph shows the total number of publications written about "Drug Resistance, Neoplasm" by people in this website by year, and whether "Drug Resistance, Neoplasm" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 2 | 2 | | 1998 | 0 | 3 | 3 | | 1999 | 0 | 2 | 2 | | 2000 | 1 | 3 | 4 | | 2001 | 0 | 3 | 3 | | 2002 | 0 | 2 | 2 | | 2003 | 0 | 4 | 4 | | 2004 | 1 | 1 | 2 | | 2005 | 3 | 4 | 7 | | 2006 | 0 | 3 | 3 | | 2007 | 4 | 9 | 13 | | 2008 | 4 | 4 | 8 | | 2009 | 6 | 5 | 11 | | 2010 | 9 | 12 | 21 | | 2011 | 4 | 10 | 14 | | 2012 | 6 | 14 | 20 | | 2013 | 10 | 16 | 26 | | 2014 | 11 | 11 | 22 | | 2015 | 11 | 14 | 25 | | 2016 | 12 | 28 | 40 | | 2017 | 13 | 20 | 33 | | 2018 | 13 | 22 | 35 | | 2019 | 17 | 11 | 28 | | 2020 | 11 | 11 | 22 | | 2021 | 12 | 12 | 24 | | 2022 | 4 | 7 | 11 | | 2023 | 1 | 7 | 8 | | 2024 | 13 | 14 | 27 | | 2025 | 13 | 11 | 24 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Resistance, Neoplasm" by people in Profiles.
-
Khong A, Ripin N, de Vasconcelos LM, Passanisi V, Spencer S, Parker R. Stress granules promote quiescence by enhancing p21 levels and reducing phospho-Rb. RNA. 2025 Sep 16; 31(10):1472-1487.
-
Nangia V, Ashraf H, Marikar N, Passanisi VJ, Ill CR, Spencer SL. MAPK and mTORC1 signaling converge to drive cyclin D1 protein production to enable cell cycle reentry in melanoma persister cells. Sci Signal. 2025 Sep 02; 18(902):eadw3231.
-
Sun Y, Fujiwara Y, Torphy RJ, Yee EJ, Guo Y, Sun Z, Hu J, Eck E, Terai T, Schulick RD, Zhu Y. CD93 blockade overcomes sunitinib resistance in pancreatic neuroendocrine tumors. Mol Ther. 2025 Oct 01; 33(10):5017-5027.
-
Skuli SJ, Bakayoko A, Kruidenier M, Manning B, Pammer P, Salimov A, Riley O, Brake-Sillá G, Dopkin D, Bowman M, Martinez-Gutierrez LN, Anderson CC, Reisz JA, Buono R, Paul M, Saland E, Liccardo F, DeVine A, Wong S, Xu JP, Nee E, Hausler R, Boettcher S, Sebti SM, Lai C, Maxwell KN, Sarry JE, Fruman DA, D'Alessandro A, Mesaros C, Keith B, Simon MC, Sung PJ, Wertheim G, Skuli N, Bowman RL, Matthews A, Carroll M. Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress response. Leukemia. 2025 Sep; 39(9):2087-2098.
-
Walker ZJ, Vaeth KF, Baldwin A, Ohlstrom DJ, Reiman LT, Dennis KA, Matlin K, Idler BM, Stevens BM, Mukherjee N, Sherbenou DW. Ribosome Profiling Reveals Translational Reprogramming via mTOR Activation in Omacetaxine-Resistant Multiple Myeloma. Mol Cancer Res. 2025 Jul 02; 23(7):611-621.
-
Sun NY, Kumar S, Kim YS, Varghese D, Mendoza A, Nguyen R, Okada R, Reilly K, Widemann B, Pommier Y, Elloumi F, Dhall A, Taniyama D, Patel M, Aber E, Contreras CF, Kaplan RN, Kiseljak-Vassiliades K, Wierman ME, Martinez D, Pogoriler J, Hamilton AK, Diskin SJ, Maris JM, Robey RW, Gottesman MM, Del Rivero J, Roper N. Identification of the Notch ligand DLK1 as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinoma. Nat Commun. 2025 Jul 01; 16(1):5511.
-
Vincze O, Spada B, Bilder D, Cagan A, DeGregori J, Gorbunova V, Maley CC, Schiffman JD, Seluanov A, Giraudeau M, Pradeu T. Advancing cancer research via comparative oncology. Nat Rev Cancer. 2025 Sep; 25(9):740-748.
-
Xing YL, Panovska D, Park JW, Grossauer S, Koeck K, Bui B, Nasajpour E, Nirschl JJ, Feng ZP, Cheung P, Habib P, Wei R, Wang J, Thomason W, Monje M, Xiu J, Beck A, Weber KJ, Harter PN, Lim M, Mahaney KB, Prolo LM, Grant GA, Ji X, Walsh KM, Mulcahy Levy JM, Hambardzumyan D, Petritsch CK. BRAF/MEK inhibition induces cell state transitions boosting immune checkpoint sensitivity in BRAFV600E-mutant glioma. Cell Rep Med. 2025 Jun 17; 6(6):102183.
-
Bazhenova L, Hodgson JG, Camidge DR, Langer CJ, Huber RM, Kim DW, Reckamp KL, Ahn MJ, Tan DSW, Patel JD, Vincent S, Li C, Humphries MJ, Zhang P, Rivera VM, Gettinger S. Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status. Clin Lung Cancer. 2025 Nov; 26(7):e503-e513.e11.
-
Monson KR, Ferguson R, Handzlik JE, Morales L, Xiong J, Chat V, Dagayev S, Khodadadi-Jamayran A, Simpson D, Kazlow E, Bunis A, Sreenivasaiah C, Ibrahim M, Voloshyna I, Ouwerkerk W, Luiten RM, Capone M, Madonna G, Lu Y, Shao Y, Pavlick A, Krogsgaard M, Mehnert J, Tang H, Dolfi S, Tenney D, Haanen JBAG, Gajewski TF, Hodi FS, Flaherty KT, Couts K, Robinson W, Puzanov I, Ernstoff MS, Rahma O, Postow M, Sullivan RJ, Luke JJ, Ascierto PA, Osman I, Kirchhoff T. Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma. Nat Med. 2025 Jul; 31(7):2385-2396.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|